Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer: a Multi-center Phase II Trial

Trial Profile

DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer: a Multi-center Phase II Trial

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2018

At a glance

  • Drugs DKN 01 (Primary) ; Atezolizumab; Paclitaxel
  • Indications Adenocarcinoma; Biliary cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms DYNAMIC
  • Most Recent Events

    • 29 Nov 2018 Status changed from planning to not yet recruiting.
    • 12 Sep 2017 New trial record
    • 08 Sep 2017 According to Leap Therapeutics media release, Leap Therapeutics will conduct this trial in collaboration with EORTC and Roche will supply atezolizumab to the EORTC for this study collaboration. Study is expected to begin enrolling patients in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top